“Term” shall mean the period commencing after the Effective Date and unless terminated earlier in accordance with the terms of this Agreement, expiring country by country of the DNDi Territory and the Entasis Territory until the longer of: (i) the expiry of any Patent Rights in such country; or (ii) ten years from the first Marketing Authorisation for such Drug Product for the Field in such country.
12. Term and Termination
12.1 This Agreement shall be effective from the Effective Date and, subject to earlier termination in accordance with its terms, it shall remain in force and effect for the duration of the Term. For the avoidance of doubt, at the expiry of the Term in each country of the DNDi Territory and the Entasis Territory, the licences granted by each Party to the other shall become perpetual.
Charles B. Holmes, MD, MPH, FIDSA, a physician and global health leader with more than 25 years of experience, brings expertise in public health policy, strengthening health systems, and the introduction and scale-up of health innovations. As Director of the Center for Innovation in Global Health at Georgetown University and Senior Advisor to Gates Medical Research Institute, he works at the intersection of science, policy, and implementation to improve health outcomes globally. His leadership experience includes serving as Chief Medical Officer and Deputy U.S. Global AIDS Coordinator at PEPFAR, Chief Executive Officer of CIDRZ in Zambia, and senior roles across academia, government, and industry. His experience building partnerships across countries, institutions, and sectors positions him to support GHIAA’s mission of advancing equitable and sustainable access to health innovations worldwide.
Sign Up to Our Newsletter
Receive updates about GHIAA’s latest tools, resources and news.
